NCT07360899Recruiting
Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture
Left Atrial Appendage Closure During Cardiac Surgery in Atrial Fibrillation Patients With Seralene
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
Atrial fibrillation is a common heart rhythm disorder that increases the risk of stroke. In patients with atrial fibrillation, blood clots most often form in a small structure of the heart called the left atrial appendage. If a blood clot travels from the heart to the brain, it can cause a stroke. Blood-thinning medications are commonly prescribed to reduce the risk of stroke in patients with atrial fibrillation. However, some patients cannot take these medications long-term because of bleeding risk, side effects, or other medical reasons. Closing the left atrial appendage is an alternative approach to reduce the risk of stroke by preventing blood from collecting in this area. When patients undergo cardiac surgery for another indication, closure of the left atrial appendage can be performed during the same operation. This study is designed to evaluate the safety and effectiveness of surgical closure of the left atrial appendage using a device called AtriLASH during cardiac surgery. AtriLASH is a surgical suture-based device intended to close the left atrial appendage. The study will assess whether the left atrial appendage can be safely and effectively closed using this method in patients with atrial fibrillation undergoing cardiac surgery. The information obtained from this study may help determine whether this approach can reduce the risk of stroke and potentially decrease the need for long-term use of blood-thinning medications in selected patients.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 6 Jan 2026
- Start date
- 1 Dec 2025
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- Institute of Cardiovascular Diseases, Vojvodina
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT07360899
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 Dec 2025 to the primary completion date, 30 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Contraindication to left atrial appendage closure (e.g., presence of left atrial appendage thrombus or unsuitable anatomy)
- Life expectancy less than 3 months, based on clinical judgment
- Current participation in another clinical study that could interfere with the outcomes of this study
- Active or suspected infective endocarditis
Who the study is looking for
- Age 18 years or older
- Documented atrial fibrillation (any type)
- CHA₂DS₂-VASc score of 2 or greater, or equivalent stroke risk
- Scheduled to undergo cardiac surgery (including coronary artery bypass grafting, valve surgery, or other structural cardiac surgery)
- Ability to understand the study and provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of cardiovascular diseases Vojvodina Coordinator of this site? Confirm its status | Kamenitz | Serbia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.